Upcoming launches of osteoporosis drug romosozumab (2017) and migraine drug erenumab (2018) should boost growth. We’re also encouraged by Amgen’s potential to enter the biosimilar market itself; ...

(Reuters) - Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this ...

DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on this site. This service is intended for adult audiences. No guarantees are made ...